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ABSTRACT 
 
Hyaluronic acid is a viscous high MW polysaccharide that is synthesized 
in the plasma membrane.  It is found in the connective tissue space, in the 
synovial fluid of movable joints and in the vitreous humor of the eye.  Its chemical 
structure is composed of a repeating disaccharide unit in which D-glucuronic acid 
is linked to the 3-position of N-acetyl-D-glucosamine.  It appears to play an 
important role in the metastasis of cancer cells since cancer cell’s CD44 
receptors adhere to it and migrate to host cells.  Our goal was to synthesize 
small HA-oligosaccharides that would behave as CD44 metastasis receptor 
antagonists.  However, HA is degraded in the liver, in the lymph nodes, as well 
as in local tissues by acid hydrolases.  Several lines of evidences have 
established that replacing the glycosidic –O– linkages with –CH2– linkages 
provides resistance to enzymatic cleavage.  Since synthesizing an all –CH2– 
linked oligosaccharide is an arduous task and virtually intractable, it was decided 
to design hydrolase-resistant HA mimics by substituting the interglycosidic 
oxygen atom with the CH2-group at strategical positions.  In this dissertation is 
described the synthesis of a –CH2– linked disaccharide to a methyl β-analog 
related to HA that can serve as a building block for the synthesis of long-chain, 
hydrolase-resistant oligosaccharide mimics.  The C-disaccharide was acquired 
from coupling a glycosyl tin derivative with an aldehyde stemming from methyl β-
D-glucopyranoside. 
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 I. INTRODUCTION 
Hyluronan (HA, also referred to as hyaluronic acid) is a natural high 
molecular mass polysaccharide, ranging from about 105 to 107 Da.  Its structure 
reveals an acidic glycosaminoglycan (GAG) made entirely of a repeating 
disaccharide unit, in which D-glucuronic acid is linked to the 3-position of N-
acetyl-D-glucosamine, i.e. [β−D−GlcNAc-(1→4) β−D−GlcA-(1→3)]n (Figure 1).1,2 It 
is the simplest of the GAGs, the only one not covalently linked to a core protein, 
not synthesized by way of the Golgi pathway, and the only non-sulfated GAG.3-6   
HA exists in vivo as a polyanion,7 encompassing a large volume of water that 
expands extacellular space, hydrates tissues, and in the dermis is responsible for 
skin moisture.  HA regulates water balance and osmotic pressure, and acts as an 
ion-exchange resin.   HA is found in the highest concentrations in typical 
connective tissues such as umbilical cord, synovial fluid, skin, and vitreous 
humor of the eye where it acts as a lubricant, a shock absorber, and as a 
structural molecule.8 Notable amounts are also present in lung, kidney, brain, 
and muscle but very little is found in the liver.  The lowest concentration is found 
in blood serum.7 HA is synthesized in the plasma membrane7,9 by a single 
enzyme, a dual-headed transferase that utilizes alternately the two uridine-5’-
diphosphosugar substrates (UDP-glucuronic acid and UDP-N-
acetylglucosamine).10,11   These add sugar units from nucleotide precursors to 
the chain by an unknown mechanism on the cytoplasmic aspect of the  
 1
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membrane and translocate the growing chain to the pericellular space.  The  
growth of the chain occurs at the reducing end.7 There are three synthase genes 
in the mammalian genome, coding for Has-1, Has-2, and Has-3 that differentially 
regulate the size of the polymer.3 Newly synthesized hyaluronan is extruded 
directly onto the cell surface; it is either retained there by sustained attachment to 
the synthase or by interactions with receptors, or it is released into the 
pericellular and extracellular matrices.12    Hyluronan participates in fundamental 
processes such as embryological development and morphogenesis, wound 
healing,13,14 repair and regeneration, and inflammation. 15-17 HA levels increase in 
response to severe stress, and in tumor progression and invasion.  It has been 
implicated in the development and progression of cancer.18,19 
 
A. Biological Background 
The presence of HA is vital to cell division and migration during normal 
development.  HA has also been shown to have a role in immune cell adhesion 
and activation, intracellular signaling, cellular growth and migration.  Although 
these properties contribute to normal tissue development and function, in cancer 
HA may promote tumor growth and metastasis.  Numerous studies performed 
over the past three decades have demonstrated a correlation between levels of 
hyaluronan production and malignancy in several types of tumor, both in animal 
models and in human patients.19-22 In the case of human breast, ovarian, and 
colon carcinomas, a high level of hyaluronan associated with cancer cells 
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themselves or with the tumor stroma is a reliable prognostic indicator of patient 
morbidity.23-25 Furthermore, studies on histological sections from various tumors, 
using a specific hyaluronan affinity probe, have indicated that virtually all human 
epithelial tumors are surrounded by a connective tissue matrix (stroma) enriched 
in hyaluronan.19 The recurrence rate of colon carcinoma after an operation 
increases from 20% to 80% with increasing levels of hyaluronan associated with 
the carcinoma cells.23 Likewise, elevated levels of hyaluronan and hyaluronidase 
in the urine form a clinically reliable marker for the presence and grade of bladder 
cancer.26 
The ancient Greeks called the disease cancer because they likened its 
gross appearance to the outwardly extended claws of the crab.27 Indeed, the 
observation that cancers extend into adjacent host tissues, invade blood vessels, 
and metastasize has been known since the early 19th century.  The spread of 
malignant tumors culminating in the establishment of one or more secondary 
tumors at a remote site is called metastasis.28 Metastasis is the major cause of 
morbidity and death for cancer patients since they succumb to multiple 
secondary tumor growths and not necessarily to the primary tumor.29,30 Tumor 
invasion by melanoma B16F10, for instance, consists of seven steps: The 
process begins with a transforming event (1), which allows local growth (2) and 
invasion of malignant cells.  These ultimately break through the basement 
membrane and invade blood vessels (3).  Once in the blood the malignant cells 
are carried to the heart (4).  Lodgment of the malignant cells in the lungs ensues 
(5), but exactly how the lodgment occurs is unclear.  Following lodgment, the 
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malignant cells extravasate (6) with enzymatic dissolution of the basement 
membrane,31 and under appropriate conditions the cells divide to form visible 
metastatic lesions (7). 32 Several types of malignant solid tumors contain 
elevated levels of hyaluronan.33 The ability of a rabbit carcinoma to invade 
surrounding tissue has been shown to correlate with its ability to induce formation 
of hyaluronate in situ,34 and a highly invasive bladder carcinoma was found to 
express high levels of hyaluronate binding activity.34 There is growing evidence 
that hyaluronan–CD44 interactions may enhance tumor growth and metastasis.35 
CD44, a multifunctional transmembrane glycoprotein, is currently thought 
to be the principal cell-surface receptor for hyaluronan.36-39 Interaction between 
cell-surface CD44 and HA is proposed to mediate, at least in part, a variety of 
cellular functions, including cell migration40, cell–matrix adhesion,34,41-43 cell–cell 
adhesion,44 lymphocyte activation,45,46 and hematopoiesis.47,48 
CD44 is highly polymorphic due to alternative splicing of at least 10 exons 
encoding a segment of the membrane proximal extracellular domain49-51 and 
variable N- and O-linked glycosylation.52-55   Multiple distinct CD44 isoforms are 
generated by incorporation of different combinations of the variable exons, which 
provide new oligosaccharide attachment sites resulting in potentially significant 
glycosylation changes.54-57 Multiple studies have indicated that malignant cells 
undoubtedly use these isoforms to facilitate migration, thus spreading cancerous 
tumors.  These facts have inspired the conception of a blueprint for the 
interactions between HA and cell-surface receptors like CD44 in metastasis.  It is 
described as follows: Migrating cancer cells exude growth factors that incite 
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neighboring cells to increase production of extracellular HA.  Migrating cancer 
cells then make use of their CD44 receptors to bind to and migrate along the 
newly synthesized HA tracks into new tissues, consequently extending 
malignancy to new tissues (Figure 2).  This current design could lead to a novel 
therapeutic approach, based on the introduction of a CD44 receptor antagonist 
that would adeptly prevent a malignant cell from binding to HA.  Unlike several 
conventional strategies that consist of cytotoxic agents that target the cell cycle, 
this approach would be acutely beneficial in cases where the tumor is highly 
metastatic or the primary tumor is untreatable.   
Almost all patients with advanced cancer will receive chemotherapy at 
some point during the treatment of their disease.  The principal limitations of 
chemotherapy in treating cancer include: treatment-related toxicities, inability to 
selectively target tumor tissue, and the development of resistance to the cancer-
killing effects of chemotherapy.  These lead to the need to design new treatment 
strategies that include the use of antiangiogenesis, anti-invasion and 
antimetastasis agents, both separately and particularly in conjunction with 
established antitumor agents. 
 
B. Biological Evaluation of HA Oligosaccharides 
as Antimetastasis Agents 
Several studies58 have led us to conclude that the early steps in the 
metastatic process, from the time the cancer cells enter the bloodstream until  
 6
 Figure 2. Blueprint for the interactions between HA and 
CD44 in cancer metastasis. 
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they extravasate into secondary organs, are completed very efficiently.  By 
contrast, subsequent steps in the metastatic process are completed inefficiently,  
with only a small subset of cancer cells in a secondary site initiating cell division 
to form micrometastases, and only a small proportion of these micrometastases 
progressively growing into macroscopic metastasis.  Therefore targeting a very 
inefficient biological process might be easier than targeting an efficient one.  
Furthermore, metastasis can rise long after the apparently successful treatment 
of a primary tumor.  In breast cancer or melanoma, for example, metastases 
have been known to occur decades after primary treatment.59,60 
Any therapy that prevents the progression of metastases to form clinically 
damaging tumors has the potential to benefit patients.  Based on this premise, on 
several studies that support the blueprint for the interactions between HA and 
cell-surface receptors like CD44 in metastasis mentioned earlier (Figure 2), and 
on Toole’s41,61 studies where treatment with HA oligosacchsrides suppressed the 
growth of tumors both in vitro and in vivo, suggesting that HA obtains new 
activities and functions after depolymerization, we propose to use HA 
oligosaccharides as CD44 metastasis receptor antagonists.  This could be 
achieved by introducing small HA oligosaccharide molecules that might out 
compete the extracellular matrix HA for the limited number of CD44 receptor 
binding sites, resulting in cancer cells no longer attaching themselves to and 
traveling along HA tracks into new tissues (Figure 3).  If this therapeutic 
approach were successful, it would involve either surgical removal or radiation on 
the primary tumor, then treatment with a CD44 antagonist that would prevent  
 8
 Figure 3. Theoretical prevention of metastasis through a 
CD44 receptor antagonist. 
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metastasis particularly in highly metastatic tumors.  Besides, in cases where the 
primary tumor is untreatable, the antimetastasis approach could prolong patient 
lives.  This idea involving non-HA type compounds such as ligand-mimicking 
drugs that efficiently block cancer-cell adhesion has been suggested for patients 
at high risk of metastasis.62,63 
To test our hypothesis, a set of experiments was conducted by our 
collaborators, Dr. Richard Cysyk and co-worker64, that can be summarized as 
follows: Malignant B16F10 melanoma cells were incubated in vitro (105 cell 
count) with a mixture of HA oligosaccharides (1 mg/mL) obtained from the 
enzymatic degradation of HA by hyaluronate lyase (EC 4.2.2.1) and injected in 
vitro into the tail vein of mice.  In a control set of experiments, the mice were 
injected with only B16F10 melanoma cells (Figure 4).  After ten days, the lungs of 
the mice, along with those of the control group were removed and examined for 
metastatic colonies.  We expected a reduction in the metastatic sites on the 
lungs of the mice that were treated with B16F10 melanoma cells, premixed with 
HA oligosaccharides.  Surprisingly, there was an almost total absence of 
metastatic lesions on these lungs, whereas the lungs of the control group 
displayed numerous tumors (Figure 5).  To ascertain the genuineness of the 
results, the experiments were repeated using a variety of controls with identical 
results.  In the sample pre-mixed with HA oligosaccharides, the viability of the 
B16F10 melanoma cells was checked as well as various other consequential 
factors.  A check for toxicity, using double and triple the amount of HA 
oligosaccharides (up to 3 mg/mL), did not uncover any toxicity.  These  
 10
 Figure 4. Mice injected with B16F10 melanoma cells. 
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experiments confirm that small HA oligos ccharides show a powerful  
o  
ists; 
C. Design of Hydrolase-Resistant 
aluronic Acid 
To ens
regula te 
e 
l is 
an 
 
er 
a
antimetastatic effect on B16F10 melanoma.  While it is still premature t
conclude that HA oligosaccharides were acting as CD44 receptor antagon
the results provide strong evidence that a small molecule can behave as an 
antimetastatic probe, which is vital to our proposed research.  Preliminary 
investigations show activity starting with the 8-mer (DP = 8). 
 
Oligosaccharides Related to Hy
ure proper cellular activity, HA levels in the body are finely 
ted to control HA biosynthesis and degradation.  A rapid turnover ra
facilitates the use of HA and its products in many physiological regulatory 
mechanisms.65 It has been estimated that about a third of hyaluronan in th
human body is removed, and replaced each day.  In many instances, remova
achieved by endocytic uptake, either within the tissue where it is made or in 
lymph nodes and the liver.7 The catabolic rate of hyaluronan greatly varies 
between tissues.66 Hyaluronan undergoes fragmentation in the presence of 
reactive oxygen species (free oxygen radicals), which can enhance hyaluron
turnover.67,68 The molecular size of HA appears to be closely related to its 
biological activity.69-73 Although HA usually exists as a high molecular mass
polymer (in excess of 10 kDa) as a component of the extracellular matrix und
physiological conditions,74 HA of a much lower molecular mass, as a result of 
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enzymatic degradation, is detected in association with certain pathological 
conditions, such as inflammation75 and tumors.76-79 Furthermore, during tum
progression, HA that has been degraded into oligosaccharides has been 
reported in urine, blood or tumor tissue specimens of the patients with tum
There is strong evidence to indicate that HA is degraded in the local tissues 
where it is produced, in the lymph and in the liver.
or 
ors.80 
lyses of 
 
β-
e 
 from the non-
81,82 Hyaluronidase is the 
enzyme responsible for HA degradation in bacteria and in mammalian 
systems.83-88 The hyaluronidases fall into three classes89 based on ana
their reaction products: (1) Bacterial hyaluronidases (EC 4.2.99.1) are endo-β-
acetyl-hexosaminidases that function as eliminases yielding disaccharides.  (2)
Endo-β-glucuronidase types of hyaluronidase (EC 3.2.1.36) found in leeches, 
crustaceans90 and some parasites, generate tetra- and hexasaccharide end-
products. (3) The mammalian types of hyaluronidase (EC 3.2.1.35) are endo-
acetyl-hexosaminidases, but function as hydrolases, with tetrasaccharides as th
predominant end-products.3 The enzyme hyaluronidase acts together with two 
exoglycosidases (β-glucoronidase (E.C. 3.2.1.31) and β-N-acetyl 
glucosaminidase (E.C. 3.2.1.30)) and removes sugars sequentially
reducing end of the polymer91 (Figure 6).  A considerable amount of evidence 
indicates that substituting the glycosidic −O− linkages with −CH2− linkages 
render oligosaccharide impervious to enzymatic or chemical hydrolysis.92-96 It is 
thought that O to CH2 substitution should lead to an alteration in both the size 
and electronic properties around the glycosidic linkage, eliminating the 
exoanomeric effect, thus allowing additional conformations around the  
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interglycosidic linkage.97 However, Sinaÿ et al. have shown that a mixed 
r to 
 
to 
d 
een −CH2− and 
.  
esis 
s 
 
nits 
synthetic C,O-pentasaccharide98,99 displays an antifactor Xa activity simila
that of the corresponding O-pentasaccharide.  Kishi’s group has demonstrated
that C-trisaccharide analogs of the H-type II human blood group antigenic 
determinant are similar in both solution conformation and biological activity 
their O-trisaccharide counterparts.100,101 Furthermore, Sinaÿ et al. have reporte
the same results for C-disaccharides, C-trisaccharides, and C-
tetrasacharides.102,103 In addition, conformational similarity betw
−O− linked disaccharides has been proven.103 Most of the published syntheses 
of linear C-saccharides have focused on the (1→6) coupling.  The Sinaÿ group 
has achieved the synthesis of a C-β-(1→6)-tetrasaccharide by the addition of a 
C-6 acetylide anion to anomeric lactone followed by stereoselective reduction102
Dondoni et al. relied upon a iterative Wittig-based approach to make a C-β-
(1→6)-pentasaccharide.104,105   The C-β-(1→2)-β-(1→4)-trisaccharide synth
by the Kishi group100 remains the highest order of its kind106,107 so far,  because 
the level of difficulty increases with the length of the chain.  Synthesizing an all 
−CH2− linked oligosaccharide is an overwhelming endeavor; therefore, we 
proposed to synthesize a “mixed” oligosaccharide, in which the −O− linkage
susceptible to hydrolytic degradation are replaced with −CH2− in order to make
the oligosaccharides hydrolytically stable.  This “mixed” oligosaccharide can 
easily be built through a confluent block synthesis approach where multiple u
of a single C-linked disaccharide (GlcNAc-GlcA) are brought together, via O-
linked coupling, n times to produce oligosaccharide of a specified length 
 16
(Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17
  
 
 
 
 
 
 
O
H2C
HO
OH
HO2CO
HO
O
NHAc
OH
O
HO
O
AcHN
OH
O
H2C
HO
OH
HO2C
O
HO
HO
AcHN
OH
O
H2C
HO
OH
HO2C
Resistance to the endo-ß-acetyl-
hexosaminidase
OH
 
 
 
Figure 7. Hydrolase-resistant hexasaccharide. 
 
 
 
 
 
 
 18
 II. STATEMENT OF THE PROBLEM 
A. 
This dissertation will focus mainly on the design and the synthesis of a C-
linked 
 
 
B. Retrosynthetic Analysis 
Ou ed” oligosaccharide that will be 
assem
e 
 in order to 
e 
s  
Objectives 
methyl β-disaccharide unit that would serve as a building block of the 
higher order C-/O- linked HA oligosaccharide mimics.  This disaccharide unit
turns out to be very challenging to make; however, the small size of the group
(methyl) at the anomeric position and its β position render it very valuable for 
NMR (nuclear magnetic resonance) spectroscopy and molecular modeling 
studies. 
 
r ultimate goal is the synthesis of a “mix
bled from a single disaccharide intermediate, GlcNAc−X−GlcA (where X= 
−CH2−) that is strategically protected so as to serve as acceptor having the 3’-
hydroxy group free or as a C-1 glycosyl donor (Figure 8).  The coupling of thes
two disaccharides will be achieved via Schmidt’s trichloroacetimidate 
glycosylation.  In addition, the GlcA moiety will be selectively protected
allow oxidation of the 6−OH to the carboxylic acid.  The C-disaccharide building 
block presented two sites of disconnection.  The first is between C-1 of the  
GlcNAc residue and the CH2 group (Figure 9), and the second is between th
CH2 group and C-4 of the GlcA unit (Figure 9).  Our group’s previous work108 ha
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Figure 8. Building blocks for C-linked oligosaccharide. 
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 unsuccessfully attempted the coupling of these two units from these two sites  
d 
me 
After investigation into a variety of options, Skrydstrup’s approach seemed 
to mak
it at 
e 
n my 
t 
s 
 
using Martin’s nitrosugar approach109,110(Scheme 1), which is extensively 
covered in Ken Price’s dissertation,111 and the tether approach that involve
intramolecular radical coupling via the condensation of phenylseleno amino 
sugar and 4−C−methylene−β−D−xylo−hexopyranosiduronic acid112,113 (Sche
2). 
e our goal more attainable.  Skrydstrup and co-workers114-117 have 
produced a C-α-disaccharide, that contains an N-acetylglucosamine subun
the nonreducing end, through samarium diiodide coupling of an α-D-glucosyl-2-
pyridysulfone with a simple aldehyde.  It was theorized that the β isomer of the 
2−pyridylsulfone would give predominately the C-β-disaccharide.  The procedur
would involve coupling a strategically protected β−2−pyridylsulfone with an 
adequately protected aldehyde (Scheme 3).  I was strongly encouraged whe
co-worker Qiang Yang using the Skrydstrup approach succeeded in obtaining 
predominantly C-β-disaccharide of a different analog.118 However, my attempt a
coupling was not as successful.  The yield was poor and I had more of the α 
isomer than the β.  At this stage, an alternative approach was needed and wa
found in the coupling of Kessler’s dianion,119-121 made from treating a glycosyl tin
derivative with methyllithium, then butyllithium, and with a strategically protected 
aldehyde (Scheme 4). This approach presents several advantages.  First, the 
yield of this reaction was much improved from the Skrydstrup approach.  
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Second, since the reaction is ionic, the stereochemical outcome can be predicted 
and only the desired β anomer was obtained.  This approach successfully used 
by my co-worker Sean K. Hamilton122 and would become the blueprint for all C-β-
disaccharide analogs synthesized in our group.    
 
C. Significance 
The synthesis of the C-disacharide mimetic related to HA provides at least 
two formidable challenges.  The first one is the generation of the desired β 
stereochemistry.  Although there are some examples in the literature, most of 
those methods give a mixture of α and β products where the α isomer 
predominates.  The second is the selective oxidation of the 6−OH group to the 
carboxylic acid.  The protecting groups have to be selected so as to allow only 
the deprotection of the 6−OH group for the oxidation, and the oxidation has to 
occur mildly enough so as not to limit the choice of protecting groups.  In 
addition, the synthesis of the methyl C-β-disaccharide turned out to be a 
formidable task due to the low yield of reactions and expensive starting material.  
However, it was needed for comparative NMR and molecular modeling studies 
with the O-linked disaccharide synthesized by my co-worker, Bin Jiang.108 
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III. RESULTS AND DISCUSSION 
A. The Skrydstrup Approach 
1. Synthesis of the Pyridyl Sulfone of 
N−Acetyl−glucosamine 5 (GlcNAc Component) 
The synthesis of compound 5 (Scheme 5) starts with commercially 
available 2-acetamido-2-deoxy-D-glucose (1) which was benzylated according to 
the Harrison and Fletcher procedure123,124 in the presence of barium oxide (BaO) 
and barium hydroxide (Ba(OH)2) to give benzyl 2-acetamido-3,4,6-tri-O-benzyl-2-
deoxy-β-D-glucopyranoside (2).  Hydrolysis of the anomeric benzyloxy group was 
achieved using a catalytic amount of a palladium-on-carbon (Pd−C) hydrogen-
transfer system in a yield of 78%.  The 2-acetamido-2-deoxy-D-glucopyranose 
derivative 3 was treated with tri-n-butylphosphine (PBu3) and 2,2’-dipyridyl 
disulfide in CH2Cl2117,125 to give the expected and chromatographically separable 
pyridyl sulfides α and β as a 1:3 anomeric mixture in high yield.  The β−pyridyl 
sulfide 4 was then treated with m-chloroperoxybenzoic acid (m-CPBA) and 
sodium carbonate (Na2CO3) in dichloromethane (CH2Cl2) at 0 οC to give pyridyl 
sulfone 5 in a good yield of 80%. 
2. Synthesis of Adehyde 15 (GlcA Component ) 
Because methyl β-D-galactopyranoside is rather expensive and the pure 
compound was not required, our synthesis commenced with the more affordable 
α,β-D-galactose pentaacetate (scheme 6).  The anomeric carbon on  
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Scheme 5. Synthesis of GlcNAc component 5. 
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Scheme 6. Synthesis of Glc aldehyde 15. 
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α,β-D-galactose pentaacetate was brominated with hydrobromic acid, (33 wt% 
solution in glacial acetic acid).  The glycosyl bromide 7 obtained from 
recrystallization in dry ether was dried and treated with zinc oxide (ZnO) in 
methanol126 at room temperature over 6 hours to give exclusively methyl tetra-O-
acetyl-β-D-galactopyranoside (8) in a 60% yield.  Deacetylation using sodium 
methoxide in methanol afforded methyl β-D-galactopyranoside (9) in an overall 
yield of 40%.  Following Samuelson and Johansson’s procedure,127,128 galactose 
derivative 12 was available from methyl β-D-galactopyranoside (9) in three steps 
in 46% overall yield.  Thus a solution of 4-methoxybenzaldehyde dimethyl acetal 
(ADMA), a catalytic amount of p-toluenesulfonic acid (TsOH), and methyl β-D-
galactopyranoside (9) in dry N,N−dimethylformamide (DMF) was placed on a 
rotatory evaporator at 45 οC for 2 hours to give galactoside 10.  Benzylation of 
the free hydroxyl groups of compound 10 using benzyl bromide and sodium 
hydride easily led to the formation of the fully protected galactose derivative 11.  
Regioselective reductive ring opening of acetal 11(scheme 7) via sodium 
cyanoborohydride (NaCNBH3), trifluoroacetic acid (CF3CO2H), and 3Ǻ molecular 
sieves (MS) in dry DMF afforded compound 12.  The galacto-triflate 13 was 
prepared by reaction of galactose derivative 12, pyridine (Pyr) and 
trifluoromethanesulfonic anhydride (Tf2O) in CH2Cl2 over a period of 3 hours.  
The triflate 13 was obtained as an oil, which when treated with dry 
tetrabutylammonium cyanide (NH4CN) in dry DMF, gave the gluco-configured 
nitrile 14 in a yield of 32%, along with 30% of the elimination product and 2% of 
an isonitrile product.  Reduction of the nitrile compound 14 with  
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diisobutylaluminium hydride (DIBALH)129 yielded 74% of the aldehyde 15. 
3. Samarium Diiodide-Promoted Coupling 
Reaction 
      With pyridyl sulfone 5 and aldehyde 15 in hand, the stage was now set 
for the samarium diiode-promoted coupling115,117 of compound 5 with aldehyde 
15 (Scheme 8).  Upon addition of a solution of samarium diiodide (2.2 equiv) to a 
tetrahydrofuran (THF) solution of compound 5 and compound 15, an 
instantaneous reaction ensued, affording a 4:1 anomeric mixture of α and β 
disaccharide 16.  However, the yield of the reaction was very low (9%).  Although 
the α/β anomeric mixture of disaccharide 16 was easily separated, and the α 
anomer can be converted to the β anomer, the very low yield of the reaction and 
the predominance of the α anomer over the β led us to investigate an alternative 
approach to making disaccharide 16b.  
 
B. Kessler’s Dianion Approach 
1. Synthesis of Glycosyl Tin Compound 19 
(GlcNAc Component) 
2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (3) was 
synthesized in four steps (Scheme 9) from commercially available 
2−acetamido−2−deoxy−D−glucose (1) by a modified procedure of Warren and 
co-workers.130,131 That is, a suspension of glycosyl derivative 1, allyl alcohol   
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and boron trifluoride etherate (BF3.Et2O) was refluxed for 2 hours to give the allyl 
glucoside 17.  Benzylation of the crude product 17 using benzyl chloride (BnCl) 
and powdered potassium hydroxide (KOH) in refluxing dioxane afforded glucose 
derivative 18.  Hydrolysis at the anomeric carbon is accomplished in two steps: 
first, isomerization of the double bond on the allyl group with potassium tert-
butoxide (KOtBu) in anhydrous dimethyl sulfoxide (DMSO), and second, removal 
of the resulting propenyl group with 2 M hydrochloric acid in a refluxing mixture of 
acetone and water.  The resulting product 3 obtained by recrystallization from 
methanol, was chlorinated with thionyl chloride in dry CH2Cl2.  The resulting 
glycosyl chloride was then treated with lithium tributyltin, which was produced by 
reacting lithium metal with tributyltin chloride, to give glycosyl tin derivative 19 in 
an overall yield of 46%. 
2. Synthesis of Aldehyde 15 (GlcA Component ) 
Earlier aldehyde 15 was synthesized from α,β-D-galactose pentaacetate 
(6) via methyl β-D-galactopyranoside (9); however, because the low yield of 
recrystallization of glycosyl bromide 7 from dry ether and especially the low yield 
of the nitrile-forming reaction to give the gluco-configured nitrile 14 (32% versus 
82% in the literature) and 30% of elimination byproduct, an alternative route was 
investigated.  Although the success of this approach was uncertain, it was 
noticed that the glycosyl bromide 21 recrystallized readily from dry ether, already 
improving the overall yield of making methyl β-D-glucopyranoside (23), which 
could lead to the galacto-configured nitrile 28.  The nitrile of the D-gluco 
configuration could then be reached via isomarization of the C-4 bond.  It was 
 36
encouraging to find that Schmidt and Preuss132 have successfully isomerized the 
more stable gluco-aldehyde from the galacto-aldehyde in 80% yield.  
Consequently, the new synthesis for aldehyde 15 starts with α,β-D-glucose 
pentaacetate (Scheme 10), and as described above methyl β-D-glucopyranoside 
(23)  was obtained in three steps in 60% overall yield (1. HBr, glacial AcOH  2. 
ZnO, MeOH  3. NaOMe, MeOH).  The gluco-triflate 27 was arrived at in four 
steps from methyl β-D-glucopyranoside (23) (1. ADMA, TsOH, DMF  2. BnBr, 
NaH, DMF  3. NaCNBH3, CF3CO2H, 3A MS, DMF  4. (Tf)2O, Pyr, CH2Cl2).  To 
our astonishment when gluco-triflate 27 (Scheme 11) was treated with dry 
tetrabutylammonium cyanide (NH4CN) in dry DMF, it gave the galacto-configured 
nitrile 28 in a yield of 64% along with barely 5% elimination product and 1% of 
isonitrile product.  Reduction of the nitrile compound 28 with diisobutylaluminium 
hydride (DIBAL-H) yielded 82% of galacto-aldehyde 29.  Triethylamine (Et3N) 
treatment of aldehyde 29 overnight at 60 οC led to the thermodynamically more 
stable gluco-aldehyde 15 in a 71% yield after separation of the two aldehydes by 
flash chromatography.  This new route afforded us an improved yield by about 
20%. 
3. Dianion-Promoted Coupling Reaction 
With glycosyl tin compound 19 and aldehyde 15 in hand, coupling was 
achieved (Scheme 12) using a modified procedure of Kessler and co-workers120.   
Glycosyl tin compound 19 was deprotonated at –78 οC with methyllithium (MeLi)  
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Scheme 10. Synthesis of Glc aldehyde 15 via aldehyde 29. 
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Scheme 11. Synthesis of aldehyde 15 via aldehyde 29 
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Scheme 12. Kessler's dianion promoted-coupling. 
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in dry THF, then transmetallated at –65 οC by butyllithium (BuLi) to give the 
intermediate 30, indicated by a deep red color of the solution.  Subsequent 
addition of aldehyde 15 provided the required disaccharide 16b, which was 
identified by mass spectrometry (Figure 10).  The C-(1→4) linkage was 
confirmed to be β by 1D and 2D (gCOSY, HSQC) NMR spectroscopy with its  
coupling constant of J1,2 = J2,3 = 10.2 Hz (Figure 11). 
Alcohol 16b was then treated, according to the Barton and McCombie 
procedure133,134, with an excess of sodium hydride (NaH) in THF containing a 
trace of imidazole as catalyst.  An excess of carbon disulfide (CS2) was added 
after one hour.  The dithiocarbonate salt that resulted from the addition of CS2 
was alkylated with excess of iodomethane (MeI) after one more hour.  Treatment 
of the resulting thioester with an excess of tributylstannane (n-Bu3SnH) and 
azoisobutyronitrile (AIBN) in refluxing toluene gave the deoxygenated 
disaccharide 31.  Compound 31 was treated with ceric ammonium nitrate 
(CAN),135,136 which selectively removed the p-methoxybenzyl group to give 
alcohol 32.  The deprotected hydroxyl 6−OH group on alcohol 32 was then easily 
oxidized to the corresponding carboxylic acid in the presence of a catalytic 
amount of 2,2,6,6-tetramethyl-piperidine-1-oxyl (TEMPO), potassium bromide, 
and tetrabutylammonium bromide under aqueous organic two-phase 
conditions.137-139 Hydrogenolytic debenzylation of the carboxylic acid was 
conducted using Pearlman’s catalyst, palladium hydroxide-on-carbon  
 41
 Figure 10. Mass spectrum of disaccharide 16b. 
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 Figure 11. Partial 1H NMR spectrum of disaccharide 16b. 
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(Pd(OH)2/C)  in  4:1methanol–ethyl acetate (MeOH–EtOAc) over 3 days under an 
atmosphere of hydrogen (H2)137,140 to finally give the elusive dissacharide 33, 
which was characterized by mass spectrometry (Figure 12).  
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 Figure 12. Mass spectrum of disaccharide 33. 
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IV. CONCLUSIONS 
The synthesis of the C-disaccharide mimetic of hyaluronic acid was 
accomplished first via samarium diiodide-promoted coupling then by an 
adaptation of Kessler’s dianion-promoted coupling methology.  The samarium 
diiodide approach gave predominantly the α-C-disaccharide over the β anomer in 
a rather poor yield, the Kessler dianion approach, however, gave almost only the 
desired β-C-disaccharide in a rather good yield for a coupling reaction.  This 
latter approach relied on the coupling of an adequately protected glycosyl tin 
derivative that acts as the glycosyl acceptor and the GlcNAc component with a 
strategically protected aldehyde that acts as the glycosyl donor and GlcA 
component of the synthesized disaccharide unit. This approach has also been 
used by my co-worker, Dr. Zhong-Xu Ren, in the synthesis of a C−/O−linked HA 
tetrasaccharide mimetic where the two disaccharide units built were strategically 
protected in order to act either as C−1 glycosyl donor (activated as 
trichloroacetimidate) or as glycosyl acceptor with the 3’−OH free.118 Thus this 
strategy should enable us to assemble C−/O−linked oligosaccharides of the 
eight-mer and beyond. 
The disaccharide achieved here will be used for NMR spectroscopy and 
molecular modeling studies, and the techniques used will add to the vast 
knowledge acquired by my group in the synthesis of HA-related oligosaccharides 
that can potentially act as antimetastatic agents. 
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V. EXPERIMENTAL 
General methods.— 1H and 13C NMR spectra were recorded at 25 οC on  a 
Varian Mercury 300, or a Varian Inova 600 instrument at resonance frequencies 
of 300 MHz or 600 MHz and 75 MHz or 150 MHz, respectively.  Chemical shift 
are reported in ppm relative to tetramethylsilane (TMS) the internal standard for 
1H and CDCl3 for 13C, unless otherwise indicated.  Multiplicities are first-order 
values in Hz: s, singlet; bs broad singlet; d, doublet; dd, doublet of doublet; t, 
triplet; dt, doublet of triplet; ddd doublet of doublet of doublet; m, multiplet. All 
two-dimensional experiments (gCOSY, HSQC, HMBC and TOCSY) were 
recorded on a Varian Inova 600.  NMR spectra of compounds are provided in the 
Appendix.  All reactions were monitored by thin-layer chromatography (TLC) on 
aluminum-backed plates coated with E. Merck silica gel and detection by 254 nm 
UV light and/or by charring with p-anisaldehyde–sulfuric acid.  Column 
chromatography was performed on 60 Ǻ (63−200 µm) and 40 Ǻ (40−60 µm) 
silica gel.  Melting points were determined with a Thomas–Hoover melting point 
instrument equipped with a Cole–Palmer model 8520-50 Digi-Sense digital 
thermocouple thermometer.  Mass spectra were acquired on a Micromass VG 
Quattro II electrospray instrument.  All organic and inorganic reagents were ACS 
grade and were used without further purification.  All solvents were freshly 
distilled by standard methods with suitable drying agents.  All moisture-sensitive 
reactions were carried out under nitrogen or argon.  Organic extracts were dried 
with anhyd. magnesium sulfate (MgSO4).  
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 Benzyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranoside (2) 
To a solution of 2-acetamido-2-deoxy-D-glucose 1 (10.0 g, 45.2 mmol) and 
benzyl bromide (91.4 mL, 768.5 mmol) in N,N-dimethylformaldehyde (DMF, 200 
mL), stirred at 0 οC, were added portionwise barium oxide (BaO, 65.15 g, 424.9 
mmol) and then barium hydroxide [Ba(OH)2, 25.7 g, 81.4 mmol].  The mixture 
was stirred at 0 οC for 5 h, and then for 18 h at room temperature.  
Dichloromethane (CH2Cl2, 200 mL) was added, and the solution was filtered.  
The organic phase was washed with water, dried and concentrated in vacuo.  
Recrystallization from MeOH afforded white crystals (75% yield) of 2; mp 160–
168 οC.   1H NMR (300 MHz, CDCl3): δ 1.81 (s, 3H, CH3), 3.5–3.8 (m, 6H), 4.04 
(dd, 1H, J = 9.6, 8.2), 4.51–4.92 (m, 6H), 4.76–4.92 (m, 5H), 5.45 (d, 1H, J = 
8.2), 7.10–7.35 (m, 20).  13C NMR (75 MHz, CDCl3): δ 23.48, 56.36, 69.03, 70.63, 
73.43, 74.45, 74.82, 78.45,74.75, 74.80, 74.92, 75.10 80.47, 99.27,127.95, 
128.09, 128.12, 128.20, 128.27, 128.33, 128.70, 128.77, 128.80, 137.87, 138.30, 
138.46, 138.71, 170.54. NMR spectral data matched that of the known 
compound.124 
 
2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (3) 
Benzyl glycoside 2 (0.86 g, 1.95 mmol), palladium-on-carbon [Pd–C, 0.70 g, 0.66 
mmol], and ammonium formate [HCO2NH4, 0.3 g, 4.8 mmol] were stirred in dry 
MeOH (30 mL) at 70 οC.  The reaction was monitored by TLC (19:1 CH2Cl2–
MeOH), and after 16 min, the mixture was filtered, and the catalyst was washed 
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with hot MeOH.  The solution was concentrated in vacuo.  Recrystallization from 
MeOH gave white crystals of tri-O-benzyl glycoside 3 in a 78% yield; mp 218–
219 οC.   1H NMR (300 MHz, CDCl3): δ 1.82 (s, 3H, CH3), 3.65 (m, 3H), 3.76 (m, 
2H), 4.02 (m, 1H), 4.12 (m, 1H), 4.54 (m, 5H), 4.8 (m, 2H), 5.2 (t, 1H, J = 3.6 Hz), 
5.35 (d, 1H, J = 9 Hz), 7.16– 7.37 (m, 15H).  13C NMR (75 MHz, CDCl3): δ 23.8, 
53.4, 69.1, 71.1, 73.8, 75.2, 75.4, 79.0, 79.7, 92.4, 128.1, 128.3, 128.4, 128.7, 
128.8, 128.83, 128.9, 138.1, 38.2, 138.7, 170.4. NMR spectral data matched that 
of the known compound.124 
 
2-Acetamido-3,4,6-tri-O-benzyl-2deoxy-β-D-glucopyranosyl 2-pyridyl sulfide 
(4) 
Tributylphosphine [Bu3P, 1.2 mL, 4.68 mmol] was added to a stirred solution of 
benzyl glycoside 3 (2.1 g, 3.6 mmol) and 2,2‘-dipyridyl disulfide (0.73 mL, 3.3 
mmol) in CH2Cl2 (60 mL).  After being stirred for 1 h, the solution was evaporated 
to dryness in vacuo.  Purification of the residue by flash chromatography 
(7:2.8:0.2 hexanes–CH3Cl–MeOH) provided pyridyl sulfide 4 in a yield of 73% 
(α/β 1/3).  1H NMR (300 MHz, CDCl3): δ 1.77 (s, 3H, CH3), 3.53–3.84 (m, 5H), 
4.13 (td, 1H, J = 10.2, 8.2 Hz), 4.45–4.60 (m, 3), 4.71–4.86 (m, 3H), 5.56 (d, 1H, 
J = 10.2 Hz), 6.06 (d, 1H, J = 8.7 Hz), 7.00 (dt, 1H, J = 6.0, 1.2 Hz), 7.18–7.31 
(m, 17H), 7.43 (t, 1H, J = 7.8 Hz), 8.37 (d, 1H, J = 4.6 Hz).  13C NMR (75 MHz, 
CDCl3): δ 23.37, 54.70, 68.80, 73.22, 74.68, 74.75, 78.14, 79.56, 82.70, 83.25, 
120.45, 123.64, 127.45, 127.67, 127.73, 127.86, 128.13, 128.21, 128.27, 128.34, 
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128.39, 136.55, 137.90, 138.02, 138.18, 149.18, 157.28, 170.26. ESIMS 
(positive-ion): m/z = 585.1 (M + H+), 607.1 (M + Na+), 623.2 (M + K+). 
 
2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl 2-pyridyl 
sulfone (5) 
m-Chloroperoxybenzoic acid (m-CPBA) of 85% purity (0.523 g, 2.58 mmol) was 
added to a stirred mixture of sulfide 4 (0.7 g, 1.2 mmol) and  sodium bicarbonate 
(NaHCO3,0.71 g, 8.4 mmol) in CH2Cl2 (10 mL) at 0 οC.  After 2.5 h TLC (1:1 
CHCl3–EtOAc) showed the reaction was completed.  The mixture was diluted 
with CH2Cl2 and then washed consecutively with a 50% satd Na2S2O3, satd 
NaCO3, and brine.  The organic phase was dried over MgSO4 and concentrated 
to dryness in vacuo.  Flash chromatography (3:1, 2:1, 1:1 CHCl3–EtOAc) gave 
sulfone 5.  1H NMR (300 MHz, CDCl3): δ 1.91 (s, 3H, CH3), 3.46–3.62 (m, 4H), 
3.90–4.00 (m, 1H), 4.17–4.28 (m, 2H), 4.46 (t, 1H, J = 9.0 Hz), 4.54 (d, 1H, J = 
11.1 Hz), 4.67–4.84 (m, 3H), 5.51 (d, 1H, 10.2 Hz), 6.32 (d, 1H, J = 5.1 Hz), 
7.10–7.39 (m, 16H), 7.77 (dt, 1H, J = 7.8, 3.6 Hz), 8.05 (d, 1H, J = 7.8 Hz), 8.66 
(d, 1H, J = 3.6 Hz).  13C NMR (75 MHz, CDCl3): δ 23.50, 52.47, 68.41, 73.03, 
74.72, 75.39, 77.87, 79.68, 80.97, 86.13, 124.54, 127.34, 127.41, 127.44, 
127.72, 127.87, 128.18, 128.31,128.36, 137.55, 137.79, 137.99, 138.14, 150.17, 
154.96, 171.40. ESIMS (positive-ion): m/z = 617.1 (M + H+), 639.1 (M + Na+), 
655.0 (M + K+). 
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 Methyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (8) 
Hydrobromic acid (9.5 mL of a 33 wt% solution in HOAc) was added to α,β-D-
galactose pentaacetate (10.7 g, 27.4 mmol), and the solution was stirred for 2 h 
(TLC 2:1 petroleum ether–EtOAc).  The reaction mixture was evaporated and co-
evaporated with dry toluene to give the corresponding glycosyl bromide.  The 
glycosyl bromide was crystallized from dry ether and dried over night.  The dried 
tetra-O-acetyl-α-D-glucopuranosyl bromide (17.1 g, 41.7 mmol) was then 
dissolved in dry MeOH (500 mL) with zinc oxide [ZnO, 2.5 g, 30.9 mmol] at 0 °C 
and allowed to warm to room temperature for 7 h (TLC 2:1 Petroleum ether–
EtoAc).  The reaction mixture was filtered, and the filtrate was concentrated.  The 
residue was dissolved in chloroform (50 mL), washed with water (15 mL x 3), 
dried over anhyd. MgSO4 and concentrated.  The crude product crystallized from 
MeOH as needles in a yield of 60% (α/β 0/100); mp 84–85 οC.   1H NMR (300 
MHz, CDCl3): δ 1.99 (s, 3H, CH3), 2.05 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.16 (s, 
3H, CH3), 3.52 (s, 3H, CH3), 3.92 (dt, 1H, J = 6.7, 1.00), 4.10–4.25 (m, 2H), 4.41 
(d, 1H, J = 8.0), 5.02 (dd, 1H, J = 10.2, 3.6), 5.21 (dd, 1H, J = 10.2, 8.0), 5.4 (dd, 
1H, J = 3.6, 0.6).  13C NMR (75 MHz, CDCl3): δ 20.88, 20.99, 21.03, 21.04, 
57.34, 62.13, 68.61, 71.46, 72.01, 73.10, 101.87, 169.69, 170.58, 170.75, 
171.03.  NMR spectral data matched that of the known compound.126 
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 Methyl β-D-galactopyranoside (9) 
To a solution of methyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (8) (7.1 g, 
19.6 mmol) in dry CH2Cl2 (10 mL) and MeOH (50 mL) was added sodium 
methoxide (25% in MeOH).  The reaction was allowed to stir at room temperature 
for 5 h, after which time it was neutralized with Dowex 50 x 2-100 (H+ form), 
filtered, and concentrated.  The crude product was crystallized from ethanol 
(EtOH) as a white amorphous solid in high yield of 70%.); mp 169–171 οC  1H 
NMR (300 MHz, CDCl3): δ 3.27 (dt, 1H, J = 8.1, 1.8 Hz), 3.35 (s, 3H, CH3), 3.42 
(dd, 1H, J = 10, 3.6 Hz), 3.45–3.5 (m, 1H), 3.53–3.58 (m, 2H), 3.69 (dd, 1H, J = 
3.6, 1.8 Hz), 4.09 (d, 1H, J = 7.8 Hz).  13C NMR (75 MHz, CDCl3): δ 57.18, 61.00, 
68.67, 70.72, 72.78, 75.15, 103.82.  NMR spectral data matched that of the 
known compound.126,141 
 
Methyl 4,6-O-(4-methoxybenzylidene)-β-D-galactopyranoside (10) 
A solution of methyl β-D-galactopyranoside (9) (10.0 g, 51.5 mmol), 4-
methoxybenzaldehyde dimethyl acetal (17.6 mL, 103.1 mmol), and p-
toluenesulfonic acid monohydrate (0.09 g, 0.51 mmol) in anhydrous DMF (50 
mL) was heated at 50 °C on a rotary evaporator under water aspirator pressure 
(~ 22 mm Hg) for 2 h.  The temperature was then increased to 70 °C, and the 
mixture was concentrated in volume to 20 mL.  This remaining solution was 
poured into stirred slurry of ice (25 g), satd aq soduim bicarbonate (50 mL), and 
diethyl ether (50 mL).  The white precipitate that formed was filtered, washed with 
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hexanes (50 mL x 3), water (50 mL x 2) to give a white solid in 84% yield.   1H 
NMR (300 MHz, CDCl3): δ 2.51 (bs, 2H), 3.45 (m, 1H), 3.56 (s, 3H, CH3), 3.60– 
3.76 (m, 2H), 3.78 (s, 3H, CH3), 4.05 (d, 1H, J = 12.6 Hz), 4.21 (d, 2H, J = 7.0 
Hz), 4.32 (d, 1H, J = 12.6 Hz), 5.48 (s, 1H), 6.83– 6.90 (m, 2H), 7.39– 7.44 (m, 
2H). 13C NMR (75 MHz, CDCl3): δ 55.51, 57.46, 66.85, 69.31, 72.02, 72.92, 
75.44, 101.50, 103.95, 113.75, 127.96, 130.14, 160.43.  ESIMS (positive-ion): 
m/z = 313.1 (M + H+), 335.0 (M + Na+), 351.1 (M + K+). 
 
Methyl 2,3-di-O-benzyl-4,6-O-( 4-methoxybenzylidene)-β-D-
galactopyranoside (11) 
Sodium hydride [60%, 13.8 g , 346.0 mmol] was washed with anhyd hexanes (3 x 
30 mL), then dispersed in anhyd DMF (300 mL) and cooled to 0 °C.  A solution of 
methyl 4,6-O-(4-methoxybenzylidene)-β-D-galactopyranoside (10) (26.9 g, 86 
mmol) in anhyd DMF (78 mL) was added dropwise to the NaH slurry.   After 15 
min benzyl bromide [BnBr, 25.0 mL, 210.0 mmol] was added dropwise over a 15 
min period. The reaction was allowed to warm to room temperature 3 h; later 
TLC (4:1 toluene–EtOAc) showed completion.  The reaction was quenched with 
MeOH (74 mL), diluted with EtOAc (1000 mL), and washed with H2O (3 x 390 
mL).  The combined aq phases were extracted with ether (800 mL). The 
combined organic phases were dried (MgSO4) and concentrated in vacuo to give 
43.3 g of an off-white residue, which was recrystalized from EtOH–acetone in a 
yield of 72%.  1H NMR (300 MHz, CDCl3): δ 3.30 (m, 1H), 3.53–3.57 (m, 1H), 
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3.58 (s, 3H, CH3), 3.79 (s, 3H, CH3), 3.85 (dd, 1H, J = 10, 5.4 Hz), 3.99 (dd, 1H, 
J = 12.6, 1.2 Hz), 4.07–4.09 (m, 1H), 4.27–4.32 (m, 2H), 4.75–4.80 (m, 3H), 4.90 
(d, 1H, J = 10.8 Hz), 5.45 (s, 1H), 6.84–6.95 (m, 2H), 7.24–7.52 (m, 12H).  13C 
NMR (75 MHz, CDCl3): δ 55.26, 57.07, 66.30, 69.13, 71.89, 73.84, 75.19, 78.41, 
79.04, 101.24, 104.65, 113.39, 127.48, 127.61, 127.70, 127.81, 128.00, 128.24, 
128.29, 130.41, 138.36,138.83, 159.98.  ESIMS (positive-ion): m/z = 493.2 (M + 
H+), 515.2 (M + Na+), 531.2 (M + K+). 
 
Methyl 2,3 di-O-benzyl-6-O-(4-methoxybenzyl)-β-D-galactopyranoside (12) 
A solution of trifluoroacetic acid [CF3CO2H, 15.6 mL, 203 mmol] in anhyd DMF 
(120 mL) over 3A MS at 0 °C was added to a slurry of methyl 2,3-di-O-benzyl-
4,6-O-4-methoxybenzylidene-β-D-galactopyranoside (11) (10.0 g 20.3 mmol), 
sodium cyanoborohydride (NaBH3CN, 6.4 g, 101.5 mmol) and crushed 3 Ǻ MS 
(10.0 g) in anhyd DMF (160 mL) at room temperature.  After 7 h the mixture was 
filtered through Celite into iced satd aq NaHCO3 (280 mL).  The aq phase was 
extracted with CH2Cl2 (160 mL x 5).  The combined organic phases were washed 
with satd aq NaHCO3 (280 mL), H2O (280 mL), and satd aq NaCl (280 mL), dried 
with MgSO4, and concentrated in vacuo to give a white solid.  This was purified 
by flash column chromatography (7:1 toluene–EtOAc) to yield 76% of colorless 
oil, which slowly solidified to a white solid.  1H NMR (300 MHz, CDCl3): δ 3.35 
(ddd, 1H, J = 5,4.6, 1.2 Hz), 3.42–3.58 (m, 2H), 3.55 (s, 3H, CH3), 3.69–3.84 (m, 
3H), 3.79 (s, 3H, CH3), 4.28 (d, 1H, J= 7.5 Hz), 4.60 (d, 1H, J =11.5 Hz), 4.7–
4.96 (m, 3H), 6.82–6.89 (m, 2H), 7.21–7.42 (m, 12H). 13C NMR (75 MHz, CDCl3): 
 54
δ 55.24, 57.02, 61.99, 72.11, 73.35, 73.52, 74.36, 75.15, 79.73, 82.19, 105.03, 
113.79, 127.53, 127.60, 127.67, 128.06, 128.27, 128.42, 130.25, 138.39, 138.73, 
159.42.  ESIMS (positive-ion): m/z = 495.2 (M + H+), 517.2 (M + Na+), 533.1 (M + 
K+). 
 
Methyl 2,3 di-O-benzyl-4-C-cyano-4-deoxy-6-O-(4-methoxybenzyl)-β-D-
glucopyranoside (14) 
To a solution of methyl 2,3-di-O-benzyl-4,6-O-(4-methoxybenzyl)-β-D-
galactopyranoside (2.7 g, 5.5 mmol) in dry CH2Cl2 (15 mL) and dry pyridine (1.4 
mL, 16.4 mmol) at –10 °C (ice–acetone)  was added dropwise 
trifluoromethanesulfonic anhydride Tf2O (1.1 mL, 6.6 mmol). The reaction was 
allowed to warm to room temperature within 3 h.   TLC (3:2 hexanes–EtOAc) 
showed complete consumption of the starting material.   The orange solution was 
passed through a plug of silica gel (3:1 hexanes–EtOAc) to yield the crude trifate 
as a pale-yellow syrup that was used as follows without further purification.   
To the triflate in dry DMF (15 mL) at –45 °C was added tetrabutylammonium 
cyanide Bu4NCN [5 mL, 1.8 M soln in THF, 1.5 equiv] 
(CAUTION! Bu4NCN is highly toxic: all manipulations were carried out with 
gloves and in a fume hood).   The stirring was continued for 10 min at 0 °C and 
allowed to warm to room tenperature.   An hour later TLC (3:2 hexanes–EtOAc) 
showed complete consumption of the triflate.   Cold 1 M aq HCl was added, and 
the organic layer was washed with satd NH4Cl solution and H2O (5 mL x 3).  The 
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organic layer was dried over anhydr MgSO4, then filtered and concentrated to 
orange syrup.  Flash column chromatography (8:1 hexanes–EtOAc) gave a 
yellow syrup in a yield of 32%.  1H NMR (300 MHz, CDCl3): δ 2.97 (t, 1H, J = 11 
Hz), 3.13 (t, 1H, J = 8.0 Hz), 3.55 (s, 3H, CH3), 3.64–3.82 (m, 4H), 3.80 (s, 3H, 
CH3), 4.27 (d, 1H, J = 7.8 Hz), 4.51 (d, 1H, J = 12 Hz), 4.57 (d, 1H, J = 11.4 Hz), 
4.69 (d, 1H, J = 10.8 Hz), 4.84–4.93 (m, 3H), 6.82–6.91 (m, 2H), 7.28–7.38 (m, 
12H).  13C NMR (75 MHz, CDCl3): δ 36.07, 55.24, 57.18, 69.18, 72.17, 73.44, 
74.93, 75.84, 79.28, 81.73, 104.73, 113.81, 117.71, 127.82, 128.03, 128.06, 
128.30, 128.41, 129.36, 129.57, 137.3, 138.02, 159.31. ESIMS (positive-ion): 
m/z = 526.2 (M+ Na+), 542.2 (M+ K+). 
 
Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-D-
glucopyranoside (15) 
To a solution of methyl 2,3-di-O-benzyl-4-C-cyano-4-deoxy-6-O-(4-
methoxybenzyl)-β-D-glucopyranoside 14 (1.2 g, 2.4 mmol) at –78 °C was added 
diisobutylaluminum hydride (DIBAL-H, 14.4 mL, 1 M soln in toluene, 6 equiv), 
and the reaction was allowed warm to room temperature overnight. TLC (3:2 
hexane–EtOAc) showed complete consumption of the starting material.  The 
clear solution was cooled to –10 °C, stirred vigorously, and treated dropwise with 
1:1 MeOH–THF (5 mL) and 1 N HCl (5 mL) stirred for 10 min at room 
temperature, diluted with Et2O (70 mL), washed with aq 1 N HCl (15 mL x 2) and 
H2O (10 mL x 3).  The organic layer was dried with MgSO4 and concentrated to 
give crude pale yellow syrup.  Flash column chromatography (5:1 Hexanes–
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EtOAc) gave a yellow syrup in a yield of 74%.   1H NMR (300 MHz, CDCl3): δ 
2.98 (dt, 1H, J = 10.5, 2.4 Hz), 3.45 (t, 1H, J = 8.1 Hz), 3.57–3.67 (m, 1H), 3.57 
(s, 3H, CH3), 3.74–3.8 (m, 1H), 3.81 (s, 3H, CH3), 3.96 (t, 1H, J = 10.5 Hz), 4.32 
(d, 1H, J = 7.8 Hz), 4.40–4.58 (m, 3H), 4.70–4.87 (m, 3H), 4.95 (d, 1H, J = 11 
Hz), 6.87–6.90 (m, 2H), 7.22–7.37 (m, 12H), 9.68 (d, 1H, J = 2.4 Hz).  13C NMR 
(75 MHz, CDCl3): δ 55.50, 57.36, 57.76, 70.5, 72.07, 73.36, 74.98, 75.37, 78.97, 
83.03, 104.97, 114.07, 127.77, 127.97, 128.06, 128.29, 128.31, 128.62, 128.65, 
129.70, 129.86, 138.19, 138.62, 159.57, 200.57. ESIMS (positive-ion): m/z = 
529.1 (M + Na+), 545.1 (M + K+). 
  
2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (3) 
A suspension of 2-acetamido-2-deoxy-D-glucose (10.0 g, 45.2 mmol), allyl 
alcohol (200 mL), and boron trifluoride.diethyl etherate (BF3.Et2O, 1.3 mL) was 
reflux for 2 h (TLC 4:1 MeCN–H2O).  The hot solution was filtered to remove 
impurities, which might have been present in the starting material.  The filtrate 
was evaporated, and the solid residue was dried in vacuo overnight.  The crude 
product was suspended in dioxane (500 mL), benzyl chloride BnCl (40 mL) and 
powdered potassium hydroxide (KOH, 30 g) were added, and the mixture was 
heated under reflux for 4 h (TLC 1:1 hexane–EtOAc).  After evaporation, the 
orange residue was extracted with CHCl3–H2O, the organic phase was dried 
(MgSO4) and evaporated, and the residue was co-evaporated with toluene and 
dried in vacuo overnight.  The crude product was suspended in anhydr dimethyl 
sulfoxide (DMSO, 60 mL) and treated with potassium tert-butoxide (KOtBu, 30 g).   
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While the mixture was stirred for 3 hours at 100°C (TLC1:1 hexane–EtOAc).   
The solultion turned dark brown.  After being cooled, the solution was diluted with 
H2O (250 mL), and the brown precipitate was filtered off, dissolved in acetone 
(125 mL), and treated with 2 M HCl (200 mL) under reflux for 30 min. H2O (1 L) 
was added and the pale-brown precipitate was filtered off.   Recrystallization from 
MeOH afforded colourless needles in a 40% yield; mp 214–216 °C.  1H NMR 
(300 MHz, CDCl3): δ 1.82 (s, 3H, CH3), 3.65 (m, 3H), 3.76 (m, 2H), 4.02 (m, 1H), 
4.12 (m, 1H), 4.54 (m, 5H), 4.8 (m, 2H), 5.2 (t, 1H, J = 3.6 Hz), 5.35 (d, 1H, J = 9 
Hz), 7.16– 7.37 (m, 15H).   13C NMR (75 MHz, CDCl3): δ 23.8, 53.4, 69.1, 71.1, 
73.8, 75.2, 75.4, 79.0, 79.7, 92.4, 128.1, 128.3, 128.4, 128.7, 128.8, 128.83, 
128.9, 138.1, 38.2, 138.7, 170.4.  NMR spectral data matched that of the known 
compound.119,120 
  
(2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl) 
tributylstannane (19) 
(Tributylstannyl)lithium was prepared by the addition of tributyltin chloride 
(Bu3SnCl, 5.2 mL, 19.0 mmol) to pieces of Li (0.34 g, 48.8 mmol) in THF (20 mL). 
After 10 to 30 min, heat evolved and LiCl precipitated, then the solution slowly 
turned dark green.  After 2 h the dark green solution was stored in the refrigerator 
overnight.  Prior to use the dark-green reagent was removed with a syringe from 
the residual Li. 
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At 20 °C and under argon, glucosyl derivative 3 (3.0 g, 6.1 mmol) was suspended 
in toluene (10 mL) and CHCl3 (10 mL) and treated with freshly distilled thionyl 
chloride SOCl2 (22.5 mL, 0.3 mmol) for 30 min.  The solution was evaporated 
and co-evaporated with CHCl3 (50 mL) to give the corresponding α-D-
glucopyranosyl chloride as a yellow crystalline moisture-sensitive solid.  This 
solid was dissolved in THF (50 mL) and added within 15 min to the solution of 
Bu3SnLi at –78 °C.  The mixture warmed to 20 °C, diluted with H2O, and 
extracted with CH2Cl2 (3 x 50 mL).  The combined organic phase was dried 
(MgSO4) and evaporated to give a yellow oily compound.  The yellow oil was 
purified by flash chromatography (4:1, 3:1 hexanes–EtOAc) and gave tin glucosyl 
derivative 19 in a 78% yield.   1H NMR (300 MHz, CDCl3): δ 0.78–1.00 (m, 15H, 
CH2, CH3), 1.2–1.36 (m, 6H, CH2), 1.77 (s, 3H, CH3), 3.25 (m, 1H), 3.38 (t, 1H, J 
= 9.2 Hz), 3.44 (d, 1H, J = 11.6 Hz), 3.62 (t, 1H, J = 9.2 Hz), 3.68 (s, 2H), 4.15 
(dt, 1H, J = 9.4, 11.6 Hz), 4.52– 4.67 (m, 4H), 4.8– 4.93 (m, 3H).   13C NMR (75 
MHz, CDCl3): δ 9.2, 13.7, 27.3, 29.1, 54.7, 69.4, 73.4 74.6, 74.9, 79.3, 83.4, 
85.5, 127.3, 127.7, 127.9, 128.3, 128.4, 138.3, 138.6, 169.4. NMR Spectra data 
matched that of the known compound.119,120 
 
Methyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (22) 
The procedure described for preparation of methyl 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranoside (8) was adopted.  Recrystallisation from MeOH gave the tetra-
O-acetyl glucopyranoside (22) as white needles in a 79% yield; mp 94–96 οC.  1H 
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NMR (300 MHz, CDCl3): δ 1.98 (s, 3H, CH3), 2.00 (s, 3H, CH3), 2.03 (s, 3H, 
CH3), 2.07 (s, 3H, CH3), 3.49 (s, 3H, CH3), 3.48–3.50 (m, 1H), 4.13 (dd, 1H, 10.5, 
1.8), 4.26 (dd, 1H, J = 10.5, 1.8 Hz), 4.41 (d, 1H, J = 8.1 Hz), 4.97 (t, 1H, J = 9.6 
Hz), 4.97 (dd, 1H, J = 9.6, 8.1 Hz), 5.19 (dd, 9.6, 7.8).   13C NMR (75 MHz, 
CDCl3): δ 20.79, 20.83, 20.85, 20.94, 57.29, 62.08, 68.56, 71.41, 71.96, 73.05, 
101.82, 169.64, 170.32, 170.53, 170.95.  NMR spectral data matched that of the 
known compound.126 
   
Methyl β-D- glucopyranoside (23) 
The procedure described for the preparation of methyl β-D-glucopyranoside (9) 
was adopted.  Recrystallisation from absolute EtOH gave the methyl β-D- 
glucopyranoside (23) as a white amorphous solid in a % yield; mp 104–106 οC   
1H NMR (300 MHz, CDCl3): δ 3.1–3.26 (m, 1H), 3.18 (s, 3H, CH3), 3.32 (dd, 1H, 
J=9.9, 7.8 Hz), 3.39–3.46 (m, 2H), 3.53 (dd, 1H, J = 12.3, 5.4 Hz), 3.63 (dd, 1H, J 
= 12.3, 1.5 Hz).   13C NMR (75 MHz, CDCl3): δ 54.97, 60.49, 69.50, 69.50, 71.18, 
71.54, 73.02, 73.05, 103.84.  NMR spectral data matched that of the known 
compound.126,141 
 
Methyl 4,6-O-(4-methoxybenzylidene)-β-D-glucopyranoside (24) 
The procedure described for the preparation of  methyl 4,6-O-(4-
methoxybenzylidene)-β-D-galactopyranoside (10) was adopted.  Methyl 4,6-O-(4-
methoxybenzylidene)-β-D-glucopyranoside (24) was precipitated out as a white 
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solid in 85% yield and was washed with hexanes, then water: mp 176–178 οC.   
1H NMR (300 MHz, CDCl3): δ 2.71 (s, 1H), 2.84 (s, 1H), 3.37 (ddd, 1H, J = 10, 
9.5,5.0 Hz), 3.40– 3.54 (m, 2H), 3.5 (s, 3H), 3.67–3.76 (m, 2H), 3.73 (s, 3H), 4.25 
(d, 1H, J = 7.5 Hz), 4.27 (dd, 1H, J = 10.5, 5.0 Hz), 5.42 (s, 1H), 6.82– 6.84 (d, 
2H, J = 8.7 Hz), 7.34– 7.36 (d, 2H, J = 8.7 Hz).   13C NMR (75 MHz, CDCl3): δ 
55.24, 57.40, 66.28, 68.55, 73.10, 74.40, 80.46, 101.75, 104.08, 113.65, 127.56, 
129.40, 160.19.  NMR spectral data matched that of the known compound.127 
 
Methyl 2,3-di-O-benzyl-4,6-O-( 4-methoxybenzylidene)-β-D-glucopyranoside 
(25) 
The procedure described for the preparation of methyl 2,3-di-O-benzyl-4,6-O-(4-
methoxybenzylidene-β-D-galactopyranoside (11) was adopted.  Recrystallisation 
from EtOH–acetone gave white crystals of methyl 2,3-di-O-benzyl-4,6-O-(4-
methoxybenzylidene)-β-D-glucopyranoside (25) in a yield of 76%: mp 150–151 
οC.   1H NMR (300 MHz, CDCl3): δ 3.41 (td, 1H, J = 10.0, 5.0 Hz), 3.45 (dd, 1H, J 
= 9.0, 7.5 Hz), 3.59 (s, 3H), 3.67 (dd, 1H, J = 10.5, 9.0 Hz), 3.77 (m, 2H), 3.82 (s, 
3H), 4.35 (dd, J = 10.5, 5.0 Hz), 4.42 (d, 1H, J=7.5 Hz), 4.82 (m, 2H), 4.85 (m, 
2H), 5.54 (s, 1H), 6.90–6.92 (m, 2H), 7.24–7.26 (m, 12H).    13C NMR (75 MHz, 
CDCl3): δ 57.18, 57.33, 65.89, 68.65, 74.96, 75.15, 80.74, 81.38, 82.11, 101.02, 
105.12, 113.50, 127.24, 127.50, 127.57, 127.92, 127.95, 128.19, 128.24,129.77, 
138.37, 138.47, 159.93. NMR spectral data matched that of the known 
compound.127  
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Methyl 2,3 di-O-benzyl-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (26) 
The procedure described for the preparation of methyl 2,3-di-O-benzyl-4,6-O-(4-
methoxybenzyl)-β-d-galactopyranoside (12) was adopted.  Flash 
chromatography (7:1 toluene–EtOAc) yielded 76% of a colorless oil that slowly 
solidified to a white solid:  1H NMR (300 MHz, CDCl3): δ 3.33–3.38 (m, 1H), 3.34 
(dd, 1H, J = 9.0, 9.0 Hz), 3.50 (s, 3H, CH3), 3.50–3.54 (m, 1H), 3.65 (m, 2H), 
3.74 (s, 3H, CH3), 4.26 (d, 1H, J = 7.5 Hz), 4.46 (d, 2H, J = 11.8 Hz), 4.75 (d, 2H, 
J = 11.3 Hz), 4.77 (d, 2H, J = 11.5 Hz), 6.79–6.83 (m, 2H), 7.18–7.31 (m, 12H). 
13C NMR (75 MHz, CDCl3): δ 55.14, 56.98, 69.90, 71.62, 73.21, 73.92, 74.55, 
75.13, 81.67, 83.91, 104.64, 113.73, 127.54, 127.67, 127.83, 127.98, 128.25, 
128.39, 129.26, 129.90, 138.42, 138.59, 159.19.  NMR spectral data matched 
that of the known compound.127 
 
Methyl 2,3 di-O-benzyl-4-C-cyano-4-deoxy-6-O-(4-methoxybenzyl)-β-D-
galactopyranoside (28) 
The procedure described for the preparation of methyl 2,3 di-O-benzyl-4-C-
cyano-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (14) was adopted.   
Flash chromatography (8:1 hexanes–EtOAc) gave methyl 2,3 di-O-benzyl-4-C-
cyano-4-deoxy-6-O-(4-methoxybenzyl)-β-D-galactopyranoside (28) as a yellow 
syrup in a 64% yield.   1H NMR (300 MHz, CDCl3): δ 3.01 (t, 1H, J = 5.1 Hz), 
3.57–3.83 (m, 5H), 3.59 (s, 3H, CH3), 3.83 (s, 3H, CH3), 4.31 (d, 1H, J = 7.8 Hz), 
4.52–4.59 (m, 2H), 4.63–4.79 (m, 2H), 4.90–4.95 (m, 2H), 6.90–6.93 (m, 2H), 
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7.29–7.38 (m, 12H).   13C NMR (75 MHz, CDCl3): δ 34.36, 55.52, 57.46, 69.47, 
72.46, 73.72, 75.22, 76.12, 78.57, 80.02, 105.02, 113.71, 117.81, 127.79, 
128.12, 128.24, 128.33, 128.36, 128.49, 128.60, 128.71, 129.66, 129.78, 129.87, 
137.62, 138.33, 159.61. ESIMS (positive-ion): m/z = 526.2 (M+Na+), 542.2 (M+ 
K+). 
 
Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-D-
galactopyranoside (29) 
The procedure described for the preparation of methyl 2,3 di-O-benzyl-4-deoxy-
4-C-formyl-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (15) was adopted.   
Flash chromatography (5:1 hexanes–EtOAc) gave methyl 2,3 di-O-benzyl-4-
deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-D-galactopyranoside (29) as a yellow 
syrup in 76% yield.   1H NMR (300 MHz, CDCl3): δ 2.90 (td, 1H, J = 5.1, 2.5 Hz), 
3.31–3.46 (m, 2H), 3.46 (m, 3H, CH3), 3.62–3.70 (m, 2H), 3.70 (s, 3H, CH3), 4.27 
(d, 1H, J =7.8 Hz), 4.29–4.50 (m, 3H), 4.63 (d, 1H, J = 11.4 Hz), 4.67 (d, 1H, J = 
11.4 Hz), 4.82 (d, 1H, J = 12.6 Hz), 6.79 (m, 2H), 6.76–4.83 (m, 12H), 9.82 (d, 
1H, J = 5.1 Hz).   13C NMR (75 MHz, CDCl3): δ 53.63, 55.20, 69.53, 71.84, 72.46, 
73.26,75.13, 79.09, 80.01, 105.37, 113.68, 127.51, 127.61, 127.69, 127.87, 
128.15, 128.20, 129.35, 137.96, 138.11, 159.32, 200.58. ESIMS (positive-ion): 
m/z = 529.1 (M + Na+), 545.1 (M + K+). 
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Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-D-
glucopyranoside (15) 
Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-D-
galactopyranoside (29) was dissolved in dry Et3N (10 mL) and heated for 48 h at 
45 °C.  The reaction solution was concentrated and flash chromatography (11:1 
hexanes–EtOAc) gave predominantly methyl 2,3 di-O-benzyl-4-deoxy-4-C-
formyl-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (15) as a colorless syrup in 
71% yield.   1H NMR (300 MHz, CDCl3): δ 2.98 (td, 1H, J = 10.5, 2.4 Hz), 3.45 (t, 
1H, J = 8.1 Hz), 3.57–3.67 (m, 1H), 3.57 (s, 3H, CH3), 3.74–3.8 (m, 1H), 3.81 (s, 
3H, CH3), 3.96 (t, 1H, J = 10.5 Hz), 4.32 (d, 1H, J = 7.8 Hz), 4.40–4.58 (m, 3H), 
4.70–4.87 (m, 3H), 4.95 (d, 1H, J = 11 Hz), 6.87–6.90 (m, 2H), 7.22–7.37 (m, 
12H), 9.68 (d, 1H, J = 2.4 Hz).   13C NMR (75 MHz, CDCl3): δ 55.50, 57.36, 57.76, 
70.5, 72.07, 73.36, 74.98, 75.37, 78.97, 83.03, 104.97, 114.07, 127.77, 127.97, 
128.06, 128.29, 128.31, 128.62, 128.65, 129.70, 129.86, 138.19, 138.62, 159.57, 
200.57. ESIMS (positive-ion): m/z = 529.1 (M + Na+), 545.1 (M + K+). 
  
Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-
methoxybenzyl)-β-D-glucopyranoside (16b)  
Under argon at –78 °C, methyllithium (MeLi, 0.5 mL, 1.4 equiv of a 1.6 M solution 
in hexanes) was added within 10 min to a solution of (2-acetamido-3,4,6-tri-O-
benzyl-2-deoxy-β-D-glucopyranosyl)tributylstannane (19) (420 mg, 0.556 mmol)  
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in THF (10 mL).  The mixture was warmed to –65 ° C, and buthyllithium (BuLi, 
0.3 mL, 1.0 equiv of a 1.6 M solution in hexanes) was added within 5 min (the 
solution turned deep red).  The subsequent addition of methyl 2,3-di-O-benzyl-4-
deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (15) (429 mg, 
0.24 mmol) changed the color of the solution to pale yellow.  After 1 h, the 
reaction was stopped with satd aq NH4Cl solution, and the mixture was left to 
warm up to room temperature, then diluted with CH2Cl2.  The organic layer was 
washed with H2O (5 mL x 2) and dried over anhydr MgSO4, then filtered and 
concentrated to yellow syrup.  Flash chromatography (4-1, 3-1 hexane–EtOAc) 
gave a pale yellow solid in 42% yield.   1H NMR (300 MHz, CDCl3): δ 1.54 (s, 3H, 
CH3), 2.26 (t, 1H, J = 9.0 Hz), 3.07 (t, 1H, J = 10.2 Hz), 3.23–3.39 (m, 1H), 3.51 
(s, 3H, CH3), 3.63–3.72 (m, 5H), 3.78 (s, 3H, CH3), 3.86–3.92 (m, 6H) 3.99 (bs, 
1H), 4.84–4.09 (m, 4H), 4.45–4.56 (m, 5H), 4.67–4.69 (m, 2H), 4.76 (d, 1H, J = 
7.2 Hz), 4.89 (d, 1H, J = 12 Hz), 5.07 (d, 1H, J = 11.4 Hz), 6.84–6.85 (m, 2H), 
7.23–7.37 (m, 27H).   13C NMR (75 MHz, CDCl3): δ 23.37, 45.71, 52.07, 55.44, 
56.90, 68.37, 69.79, 71.14, 73.14, 73.63, 74.09, 74.25, 74.91, 78.42, 78.82, 
79.21, 83.66, 104.67, 113.84, 127.81, 127.94, 128.05, 128.10, 128.19, 128.29, 
128.38, 128.42, 128.58, 128.66, 128.79, 128.86, 129.62, 130.96, 137.80, 138.23, 
138.56, 138.75, 158.90, 170.39. ESIMS (positive-ion): m/z = 982.7 (M + H+), 
1004.6 (M + Na+), 1020.4 (M + K+). 
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Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylmethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-
glucopyranoside (31) 
A mixture of methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-
β-D-glucopyranoside (16b)  (242 mg, 0.25 mmol) and imidazole (1.7 mg), NaH 
dispersion (80%, 43.3 mg) and dry THF (10 ml) was stirred for 1 h at room 
temperature.  CS2 (0.25 mg, 4.2 mmol) was added with stirring that continued for 
1h. Iodomethane (MeI, 0.07 mL, 1.10 mmol) was added with stirring.  TLC of the 
reaction mixture after an additional h showed complete consumption of the 
starting alcohol.  The mixture was diluted with CH2Cl2 and poured into H2O.  The 
organic layer was separated, and the aqueous layer was extracted with CH2Cl2 
(30 mL x 3).  The combined organic layers were dried over anhydr MgSO4 and 
concentrated to yellow syrup. Flash chromatography (2:1 petroleum ether–
EtOAc) gave the thiocarbonyl compound as a pale-yellow syrup.  
The thiocarbonyl compound (169 mg, 0.16 mmol) and 2,2’-azobisisobutyronitrile 
AIBN (1.3 mg) in anhydrous toluene (10 mL) was added to a refluxing solution of 
n-Bu3SnH (0.23 mL, 0.91 mmol) in anhyd. toluene (5 mL) under argon.  Heating 
was stopped after 40 min, and the reaction was allowed to cool to room 
temperature.  Toluene was added, and the solvent was evaporated.  Flash 
chromatography of the crude material gave methyl 4-C-(2-acetamido-2-deoxy-
3,4,6-tri-O-benzyl-β-D-glucopyranosylmethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-
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methoxybenzyl)-β-D-glucopyranoside (31) as a colorless syrup in a 78% yield.   
1H NMR (300 MHz, CDCl3): δ 0.85–0.90 (m, 1H), 1.58 (s, 3H, CH3), 1.81 (m, 1H), 
2.26 (t, 1H, J = 9.6 Hz), 3.09 (t, 1H, J = 10.2 Hz), 3.20–3.23 (m, 1H), 3.32–3.34 
(m, 1H), 3.44–3.88 (m, 11H), 3.51 (s, 3H, CH3), 3.76 (s, 3H, CH3), 4.25 (d, 1H, J 
= 7.5 Hz), 3.39–4.53 (m, 7H), 4.61-4.76 (m, 3H), 5.16 (d, 1H, J = 9 Hz), 6.82–
6.86 (m, 2H), 7.22–7.33 (m, 25H).   13C NMR (75 MHz, CDCl3): δ 23.37, 29.95, 
45.75, 52.10, 55.45, 56.90, 68.38, 69.81, 71.17, 73.15, 73.65, 73.90, 74.12, 
74.26, 74.91, 78.27, 78.44, 78.84, 79.23, 83.61, 83.67, 104.69,113.87, 127.82, 
127.92, 127.95, 128.06, 128.11, 128.21, 128.30, 128.39, 128.43, 128.60, 128.67, 
128.80, 128.87, 129.64, 130.97, 138.25, 138.38, 138.58, 138.61, 138.78, 159.21, 
170.67. ESIMS (positive-ion): m/z = 966.4 (M + H+), 988.4 (M + Na+), 1004.4 (M 
+ K+). 
 
Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylmethyl)-2,3-di-O-benzyl-β-D-glucopyranoside (32) 
Ceric ammonium nitrate (CAN, 0.18 g, 0.33 mmol) was added at once to a 
solution of compound methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylmethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-
glucopyranoside (31) (64 mg, 0.069 mmol) in 4:1 CH3CN–H2O (2 mL).  After the 
yellow solution had stirred for 5 min, CH2Cl2 (5 mL), H2O (1 mL), and brine (2 
mL) were added.  The organic layer was separated, and the aqueous layer was 
extracted with CH2Cl2 (5 mL x 3).  The combined organic layer was dried with 
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MgSO4 and evaporated to give a pale-yellow syrup.  Flash chromatography (1:1 
Petroleum ether-EtOAc) gave the intermediate alcohol (6-OH) 32 in 69% yield.  
1H NMR (300 MHz, CDCl3): δ 0.86–0.89 (m, 1H), 1.50 (s, 3H, CH3), 2.00–2.02 
(m, 1H), 2.26–2.29 (m, 1H), 3.22–3.8 (m, 11H), 3.44 (s, 3H, CH3), 4.14 (d, 1H, J 
= 7.2 Hz), 4.41–4.59 (m, 7H), 4.64 (d, 1H, J = 11 Hz), 4.78–4.87 (m, 4H), 4.93 (d, 
1H, J = 10.8  Hz), 7.16-7.37 (m, 25H).  13C NMR (75 MHz, CDCl3): δ 23.13, 
29.94, 46.29, 51.55, 56.82, 64.86, 66.59, 69.69, 73.56, 73.76, 74.22, 74.52, 
74.91, 75.29, 78.14, 78.97, 79.24, 79.33, 82.05, 83.98, 105.02, 127.50, 127.94, 
127.99, 128.06, 128.35, 128.43, 128.49, 128.67, 128.82, 129.04, 137.81, 138.01, 
138.47, 138.63, 139.18, 139.42, 172.52. ESIMS (positive-ion): m/z = 846.3 (M + 
H+), 868.4 (M + Na+), 884.4 (M + K+). 
 
Methyl 4-C-(2-acetamido-2-deoxy-β-D-glucopyranosylmethyl)-4-deoxy-β-D-
glucopyranosiduronic acid (33) 
To a solution of the alcohol (34.2 mg, 0.04 mmol) in CH2Cl2 (1 mL) containing 
2,2,6,6-tetramethyl-1-piperidinyloxy [TEMPO, 0.07 mg, 0.40 µmol] was added a 
solution of saturd aq NaHCO3 (0.08 mL) containing potassium KBr  (0.45 mg, 
3.80 µmol) and Bu4NBr (0.6 mg, 1.9 µmol).  The mixture was cooled to 0 °C and 
a solution of NaOCl (1,3 M, 0.1 mL), NaHCO3 (0.045 mL) and brine (0.09 mL) 
were added dropwise over 45 min TLC (12:1:1 CHCl3–CH3OH–AcOH).  The two 
layers were separated, and the organic extract was washed with H2O (2 mL x 3).  
The combined aq extracts were acidified with 4 M HCl and extracted with EtOAc 
(5 x 15 mL), dried over MgSO4, concentrated and dried overnight. 
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To a solution of the acid in 4:1 MeOH–EtOAc, 28 mg of Pd(OH)2 -on-carbon and 
a drop of HOAc were added under H2 .  The mixture was allowed to stir for 3 
days and then filtered through Celite.  The filtrate was evaporated to give an oily 
compound.  Flash chromatography on LH-20 and HP-20 provided compound 33 
in a 34% overall yield. ESIMS (positive-ion): m/z = 411.0 (M + D+). 
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1H NMR (300 MHz, CDCl3) Spectrum for Benzyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranoside (2) 
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 1H NMR (300 MHz, CDCl3) Spectrum for 2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (3)  
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13C NMR (75 MHz, CDCl3) spectrum for 2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (3) 
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1H NMR (300 MHz, CDCl3) Spectrum for 2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl 2-
pyridyl sulfide (4) 
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13C NMR (300 MHz, CDCl3) spectrum for 2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl 2-
pyridyl sulfide (4) 
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1H NMR (300 MHz, CDCl3) Spectrum for 2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl 2-
pyridyl sulfone (5) 
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13C NMR (300 MHz, CDCl3) spectrum for 2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl 2-
pyridyl sulfone (5) 
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1H NMR (300 MHz, CDCl3) Spectrum for Methyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (8) 
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1H NMR (300 MHz, CDCl ) Spectrum for Methyl 4,6-O-(4-methoxybenzylidene)-β-D-galactopyranoside (10) 3
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 13C NMR (75 MHz, CDCl3) spectrum for Methyl 4,6-O-(4-methoxybenzylidene)-β-D-galactopyranoside (10) 
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1H NMR (300 MHz, CDCl ) Spectrum for Methyl 2,3-di-O-benzyl-4,6-O-(4-methoxybenzylidene-β-D-
galactopyranoside (11) 
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13C NMR (300 MHz, CDCl3) spectrum for Methyl 2,3-di-O-benzyl-4,6-O-(4-methoxybenzylidene-β-D-
galactopyranoside (11) 
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13C NMR (300 MHz, CDCl ) spectrum for Methyl 2,3 di-O-benzyl-4,6-O-(4-methoxybenzyl)-β-D-
galactopyranoside (12) 
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1H NMR (300 MHz, CDCl3) Spectrum for Methyl 2,3-di-O-benzyl-4-C-cyano-4-deoxy-6-O-(4-
methoxybenzyl)-β-D-glucopyranoside (14) 
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 13C NMR (75 MHz, CDCl ) spectrum for Methyl 2,3-di-O-benzyl-4-C-cyano-4-deoxy-6-O-(4-methoxybenzyl)-β-
D-glucopyranoside (14) 
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1H NMR (300 MHz, CDCl3) Spectrum for Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-
glucopyranoside (15) 
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13C NMR (75 MHz, CDCl ) spectrum for Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-
methoxybenzyl)-β-D-glucopyranoside (15) 
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   1H NMR (300 MHz, CDCl3) Spectrum for Methyl 2,3 di-O-benzyl-4,6-O-(4-methoxybenzyl)-β-D-
glucopyranoside (26) 
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1H NMR (300 MHz, CDCl ) Spectrum for Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-methoxybenzyl)-β-
D-galactopyranoside (29) 
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13C NMR (75 MHz, CDCl ) spectrum for Methyl 2,3 di-O-benzyl-4-deoxy-4-C-formyl-6-O-(4-
methoxybenzyl)-β-D-galactopyranoside (29) 
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gCOSY (600 MHz, CDCl3) full spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (16b)  
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gCOSY (600 MHz, CDCl3) full spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6- tri-O-benzyl-β- D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (16b)  
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gCOSY (600 MHz, CDCl3) partial spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (16b) 
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HSQC (600 MHz, CDCl3) partial spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (16b) 
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HSQC (600 MHz, CDCl3) partial spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside 
(16b) 
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HSQC (600 MHz, CDCl3) partial spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (16b) 
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ROESY (600 MHz, CDCl3) full spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (16b)  
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ROESY (600 MHz, CDCl3) full spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6- tri-O-benzyl-β-D-
glucopyranosylhydroxymethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (16b)  
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1H NMR (300 MHz, CDCl ) Spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylmethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (31) 
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 13C NMR (75 MHz, CDCl3) spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylmethyl)-2,3-di-O-benzyl-4-deoxy-6-O-(4-methoxybenzyl)-β-D-glucopyranoside (31) 
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 1H NMR (300 MHz, CDCl ) Spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylmethyl)-2,3-di-O-benzyl-β-D-glucopyranoside (32) 
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13C NMR (75 MHz, CDCl ) spectrum for Methyl 4-C-(2-acetamido-2-deoxy-3,4,6-tri-O-benzyl-β-D-
glucopyranosylmethyl)-2,3-di-O-benzyl-β-D-glucopyranoside (32) 
3
 
 121
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VITA 
 
Kpakpo Ambroise Akué was born in Aného, Togo.  After completing his early 
education in Abidjan, Ivory Coast, he returned to Lomé, Togo, where he 
completed his Bachelor’s of Science Degree in Chemistry at the Université du 
Benin in 1997.  Then he migrated to the United State of American, joined the 
research group of Dr. David C. Baker in 1999 and obtained his Doctor of 
Philosophy Degree at the University of Tennessee in 2005. He has accepted a 
postdoctoral position in the Research and Development Department of 
PharmAgra Labs Inc in Asheville, North Carolina. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122
